3-fluoro-5-methoxybenzoyl chloride | 1092789-19-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-fluoro-5-methoxybenzoyl chloride
• 英文别名: 3-Fluoro-5-methoxybenzoyl chloride
• CAS: 1092789-19-9
• 化学式: C₈H₆ClFO₂
• 分子量: 188.586
• InChiKey: ULZCPYFUBHZFGG-UHFFFAOYSA-N

物化性质

• 沸点：
  233.1±20.0 °C(Predicted)
• 密度：
  1.309±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-fluoro-5-methoxybenzoyl chloride 在 吡啶 、 ammonium hydroxide 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 异丙醇 为溶剂， 反应 10.0h， 生成 2-(3-fluoro-5-methoxyphenyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-4(3H)-one
  参考文献：
  名称：

  Crystal Structures of PI3Kα Complexed with PI103 and Its Derivatives: New Directions for Inhibitors Design

  摘要：

  The phosphatidylinositol 3-kinase (PI3K) signaling pathway plays important roles in cell proliferation, growth, and survival. Hyperactivated PI3K is frequently found in a wide variety of human cancers, validating it as a promising target for cancer therapy. We determined the crystal structure of the human PI3K alpha-PI103 complex to unravel molecular interactions. Based on the structure, substitution at the R-1 position of the phenol portion of PI103 was demonstrated to improve binding affinity via forming a new H-bond with Lys802 at the bottom of the ATP catalytic site. Interestingly, the crystal structure of the PI3K alpha-9d complex revealed that the flexibility of Lys802 can also induce additional space at the catalytic site for further modification. Thus, these crystal structures provide a molecular basis for the strong and specific interactions and demonstrate the important role of Lys802 in the design of novel PI3K alpha inhibitors.

  DOI：

  10.1021/ml400378e
• 作为产物：
  描述：

  3-氟-5-甲氧基苯甲酸 在 N,N-二甲基甲酰胺 草酰氯 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 3-fluoro-5-methoxybenzoyl chloride
  参考文献：
  名称：

  Kinase antagonists

  摘要：

  本发明提供了一种新型化合物，它们是 PI3 激酶、PI3 激酶和酪氨酸激酶、PI3 激酶和 mTOR，或者 PI3 激酶、mTOR 和酪氨酸激酶的拮抗剂。

  公开号：

  US20070293516A1

文献信息

• INDOLINONE ANALOGUES
  申请人：ENGELHARDT Harald

  公开号：US20140296229A1

  公开（公告）日：2014-10-02

  The present invention encompasses compounds of general formula (I) wherein the groups R 1 to R 4 , A 1 and A 2 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.

  本发明涵盖了一般式（I）的化合物， 其中基团R1至R4，A1和A2具有权利要求和说明书中给定的含义。本发明的化合物适用于治疗以细胞过度或异常增殖为特征的疾病，包括含有这些化合物的药物制剂以及它们作为药物的用途。
• [EN] INDOLINONE ANALOGUES AS BRD4 INHIBITORS<br/>[FR] ANALOGUES D'INDOLINE EN TANT QU'INHIBITEURS DE BRD4
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014154760A1

  公开（公告）日：2014-10-02

  The present invention encompasses compounds of general formula (I) wherein the groups R1 to R4, A1 and A2 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.

  本发明涵盖了一般式（I）中的化合物，其中基团R1至R4，A1和A2具有权利要求和说明书中给定的含义。本发明的化合物适用于治疗以细胞过度或异常增殖为特征的疾病，包括含有这些化合物的药物制剂以及它们作为药物的用途。
• Kinase antagonists
  申请人：Knight A. Zachary

  公开号：US20070293516A1

  公开（公告）日：2007-12-20

  The present invention provides novel compounds that are antagonists of PI3 kinase, PI3 kinase and tryosine kinase, PI3Kinase and mTOR, or PI3Kinase, mTOR and tryosine kinase.

  本发明提供了一种新型化合物，它们是 PI3 激酶、PI3 激酶和酪氨酸激酶、PI3 激酶和 mTOR，或者 PI3 激酶、mTOR 和酪氨酸激酶的拮抗剂。
• Discovery of Imidazo[1,2-<i>b</i>]thiazole Derivatives as Novel SIRT1 Activators
  作者：Chi B. Vu、Jean E. Bemis、Jeremy S. Disch、Pui Yee Ng、Joseph J. Nunes、Jill C. Milne、David P. Carney、Amy V. Lynch、Jesse J. Smith、Siva Lavu、Philip D. Lambert、David J. Gagne、Michael R. Jirousek、Simon Schenk、Jerrold M. Olefsky、Robert B. Perni

  DOI：10.1021/jm8012954

  日期：2009.3.12

  series of imidazo[1,2-b]thiazole derivatives is shown to activate the NAD+-dependent deacetylase SIRT1, a potential new therapeutic target to treat various metabolic disorders. This series of compounds was derived from a high throughput screening hit bearing an oxazolopyridine core. Water-solubilizing groups could be installed conveniently at either the C-2 or C-3 position of the imidazo[1,2-b]thiazole

  已显示一系列咪唑并[1,2- b ]噻唑衍生物可激活NAD +依赖性脱乙酰基酶SIRT1，这是治疗各种代谢疾病的潜在新治疗靶标。该系列化合物是从带有恶唑烷吡啶核的高通量筛选命中获得的。水溶性基团可方便地安装在咪唑并[1,2- b ]噻唑环的C-2或C-3位置。可以通过修饰这些咪唑并[1,2- b ]噻唑衍生物的酰胺部分来调节SIRT1酶的活性。该系列中最有效的类似物，即化合物29，已在ob / ob小鼠模型，饮食诱发的肥胖（DIO）小鼠模型和Zucker fa / fa大鼠模型中证明了口服降糖活性。
• [EN] 2-ARYLNAPHTHYRIDIN-4-ONES AS POTENT ANTITUMOR AGENTS TARGETING TUMORIGENIC CELL LINES<br/>[FR] 2-ARYLNAPHTYRIDIN-4-ONES EN TANT QU'AGENTS ANTITUMORAUX PUISSANTS CIBLANT DES LIGNÉES CELLULAIRES TUMORIGÈNES
  申请人：KUO SHENG-CHU

  公开号：WO2014179401A1

  公开（公告）日：2014-11-06

  In order to search for new antitumor drug candidates from 2-arylnaphthyridin-4-ones (ANs), we have designed and synthesized a series of 3 '-hydroxy or 6-hydroxy derivatives of ANs. Following the antitumor activity screening, most of these compounds were found to exhibit significant activity. Among them, 2-(3-hydroxyphenyl)-5-methyl-1,8-naphthyridin-4(1H)-one (67) was the most promising. In a preliminary action mechanism study, the treatment of Hep3B hepatoma cells with compound (67) reveals that its mechanism of action is affect on microtubule and metastasis-related proteins. Then, the corresponding phosphate prodrug (86) of compound (67) was tested against Hep3B xenograft nude mice model for antitumor activity.

  为了从2-芳基萘啉并酮（ANs）中寻找新的抗肿瘤药物候选物，我们设计并合成了一系列ANs的3'-羟基或6-羟基衍生物。经过抗肿瘤活性筛选，发现其中大多数化合物表现出显著的活性。其中，2-(3-羟基苯基)-5-甲基-1,8-萘啉-4(1H)-酮（67）是最有前途的。在初步的作用机制研究中，用化合物（67）处理Hep3B肝癌细胞表明其作用机制影响微管和与转移相关的蛋白质。然后，化合物（67）的相应磷酸酯前药（86）被用于对Hep3B异种移植裸鼠模型进行抗肿瘤活性测试。